



Press
Release

TSXV: ADK

For immediate distribution
Source: DIAGNOS inc.

10.04.07

DIAGNOS and Carl Zeiss Canada announce agreement

Brossard, Quebec, Canada – April 7, 2010 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today that it has signed an agreement with Carl Zeiss Canada Ltd. (“Zeiss” or “CZC”) following the Memorandum of Understanding signed October 20th, 2009.

“We are pleased to proceed with a mutually beneficial formal agreement with Zeiss comprised of (1) a distribution agreement enabling the Zeiss sales force to sell CARA into its existing Canadian hospital and scientific install base, and (2) an agreement for DIAGNOS to resell Zeiss fundus cameras into new vertical markets in Canada for Zeiss. The agreement provides for mutually beneficial revenue sharing.” said Andre Larente, CEO of DIAGNOS.

“We are pleased to be moving ahead with this agreement further reinforcing our position at the forefront of ophthalmic imaging. The worldwide Diabetic epidemic is growing at an alarming pace and we will be directly supporting solutions to help in the early detection of diabetic retinopathy. Retinopathy screening projects with DIAGNOS’ technology will make it easier to screen larger groups of diagnosed and suspected diabetes patients and help preserve their vision. The agreement initially covers Canada, and we are pleased with the revenue sharing philosophy that DIAGNOS has implemented to make this a successful endeavour.” said Mike Dimitrov, Director of Market Development for Carl Zeiss Canada Ltd, Medical Products Group.

About the DIAGNOS / Carl Zeiss Canada Ltd Relationship

Under the terms of the Memorandum of Understanding between DIAGNOS and Carl Zeiss Canada Ltd, the two parties have been working closely to assure compatibility between DIAGNOS’ Computer Assisted Retinal Analysis (CARA) technology and Zeiss’ fundus camera and associated imaging software VisuPac. The parties are engaged in pilot projects aimed at testing the integrated Carl Zeiss Canada Ltd, / DIAGNOS offering in the Canadian marketplace.

About Carl Zeiss Canada Ltd

Carl Zeiss Canada Ltd was founded in 1963 with the scientific division selling and servicing laboratory and surgical microscopes and related products. In 1979 the optical division was added to supply Zeiss eye glasses to the Canadian market. By 1992, the optical division had grown into a full service optical lab with lens surfacing and coating capabilities. In 2002, Carl Zeiss Canada expanded further by reintroducing the Carl Zeiss Meditec line of ophthalmic diagnostic equipment to its medical sales and service group.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, President and CEO
Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.com